Akamine, Y., Yasui-Furukori, N., Ieiri, I. and Uno, T. (2012). Psychotropic drug–drug interactions involving P-glycoprotein. CNS Drugs, 26(11), 959–973.
Awad, A. G. (1993). Subjective response to neuroleptics in schizophrenia. Schizophrenia Bulletin, 19(3), 609–618.
Awad, A. G., Hogan, T. P., Voruganti, L. N. P. and Heslegrave, R. J. (1995). Patients’ subjective experiences on antipsychotic medications: implications for outcome and quality of life. International Clinical Psychopharmacology, 10(Suppl 3), 123–132.
Bailey, D. G., Spence, J. D., Munoz, C. and Arnold, J. M. O. (1991). Interaction of citrus juices with felodipine and nifedipine. The Lancet, 337(8736), 268–269.
Bailey, D. G., Dresser, G. K. and Bend, J. (2003). Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. Clinical Pharmacology and Therapeutics, 73(6), 529–537.
Baune, B. T., Dannlowski, U., Domschke, K. et al. (2010). The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biological Psychiatry, 67(6), 543–549.
Bousman, C. A. and Hopwood, M. (2016). Commercial pharmacogenetic-based decision-support tools in psychiatry. The Lancet Psychiatry, 3(6), 585–590.
Bousman, C. A., Sarris, J., Won, E. S. et al. (2014). Escitalopram efficacy in depression: a cross-ethnicity examination of the serotonin transporter promoter polymorphism. Journal of Clinical Psychopharmacology, 34(5), 645–648.
Bradford, L. D. (2002). CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics, 3(2), 229–243.
Carrillo, J. A., Herraiz, A. G., Ramos, S. I., Benítez, J. (1998). Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. Journal of Clinical Psychopharmacology, 18(4), 311–316.
Escobar, J. I. and Tuason, V. B. (1980). Antidepressant agents – a cross-cultural study. Psychopharmacology Bulletin, 16(3), 49–52.
Fontana, R. J., Lown, K. S., Paine, M. et al. (1999). Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterology, 117(1), 89–98.
Fricke-Galindo, I., Cespedes-Garro, C., Rodrigues-Soares, F. et al. (2016). Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations. The Pharmacogenomics Journal, 16(2), 113–123.
Fuhr, U. (1998). Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Safety, 18(4), 251–272.
Goldman, N., Glei, D. A., Lin, Y-H. and Weinstein, M. (2010). The serotonin transporter polymorphism (5-HTTLPR): allelic variation and links with depressive symptoms. Depression and Anxiety, 27(3), 260–269.
Goldstein, J. A., Ishizaki, T., Kan, C. et al. (1997). Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics, 7(1), 59–64.
Grant, D. M., Morike, K., Eichelbaum, M. and Meyer, U. A. (1990). Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. The Journal of Clinical Investigation, 85(3), 968–972.
Gunes, A. and Dahl, M. L. (2008). Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics, 9(5), 625–637.
Harris, R. Z., Jang, G. R. and Tsunoda, S. (2003). Dietary effects on drug metabolism and transport. Clinical Pharmacokinetics, 42(13), 1071–1088.
Hicks, J. K., Bishop, J. R., Sangkuhl, K. et al. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clinical Pharmacology and Therapeutics, 98(2), 127–134.
Kappas, A., Anderson, K. E., Conney, Allan H. and Alvares, Alvito P. (1976). Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. Clinical Pharmacology and Therapeutics, 20(6), 643–653.
Lee, R. P. (1980). Perceptions and uses of Chinese medicine among the Chinese in Hong Kong. Culture, Medicine and Psychiatry, 4(4), 345–375.
Lin, H. J., Han, C. Y., Lin, B. K. and Hardy, S. (1993). Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. American Journal of Human Genetics, 52(4), 827–834.
Lin, K. M. and Smith, M. W. (2000). Psychopharmacotherapy in the context of culture and ethnicity. In Ethnicity and Psychopharmacology, ed. Ruiz, P.. Washington DC: American Psychiatric Press, pp. 1–36.
Madhusoodanan, S., Velama, U., Parmar, J. et al. (2014). A current review of cytochrome P450 interactions of psychotropic drugs. Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists, 26(2), 120–138.
Mannel, M. (2004). Drug interactions with St John’s wort: mechanisms and clinical implications. Drug Safety, 27(11), 773–797.
Mantonakis, J., Markidis, M., Kontaxakis, V. and Liakos, A. (1985). A scale for detection of negative attitudes towards medication among relatives of schizophrenic patients. Acta Psychiatrica Scandinavica, 71(2), 186–189.
Murphy, E. and McMahon, F. J. (2013). Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations. Discovery Medicine, 16(87), 113–122.
Ng, C. H. (2008). Research directions in ethno-psychopharmacology. In Ethno-Psychopharmacology: Advances in Current Practice, ed. Ng, C. H., Lin, K. M., Singh, B. and Chiu, E.. New York, Cambridge University Press, pp. 169–176.
Ng, C. and Klimidis, S. (2008). Cultural factors and the use of psychotropic medications. In Ethno-Psychopharmacology: Advances in Current Practice, ed. Ng, C. H., Lin, K. M., Singh, B. and Chiu, E.. New York: Cambridge University Press, pp. 123–134.
Ng, C. H., Schweitzer, I., Norman, T., Easteal, S. (2004). The emerging role of pharmacogenetics: implications for clinical psychiatry. The Australian and New Zealand Journal of Psychiatry, 38(7), 483–489.
Ng, C. H., Chong, S. A., Lambert, T. et al. (2005). An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. International Clinical Psychopharmacology, 20(3), 163–168.
Ng, C. H., Easteal, S., Tan, S. et al. (2006). Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30(5), 953–957.
Ng, C., Sarris, J., Singh, A. et al. (2013). Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. Human Psychopharmacology, 28(5), 516–522.
Obach, R. S. (2000). Inhibition of human cytochrome P450 enzymes by constituents of St John’s Wort, an herbal preparation used in the treatment of depression. The Journal of Pharmacology and Experimental Therapeutics, 294(1), 88–95.
Ozawa, S., Soyama, A., Saeki, M. et al. (2004). Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metabolism and Pharmacokinetics, 19(2), 83–95.
Padmanabhan, S. (2014). Handbook of Pharmacogenomics and Stratified Medicines. London and San Diego: Academic Press.
Palma-Aguirre, J. A., Nava Rangel, J., Hoyo-Vadillo, C., et al. (1994). Influence of Mexican diet on nifedipine pharmacodynamics in healthy volunteers. Proceedings of the Western Pharmacology Society, 37, 85–86.
Pantuck, E. J., Pantuck, C. B., Garland, W. A. et al. (1979). Stimulatory effect of brussels sprouts and cabbage on human drug metabolism. Clinical Pharmacology and Therapeutics, 25(1), 88–95.
Perera, V., Gross, A. S. and McLachlan, A. J. (2012). Influence of environmental and genetic factors on CYP1A2 activity in individuals of South Asian and European ancestry. Clinical Pharmacology and Therapeutics, 92(4), 511–519.
Pi, E. H. and Gray, G. E. (1998). A cross-cultural perspective on psychopharmacology. Essential Psychopharmacology, 2, 233–262.
Pollock, B. G., Ferrell, R. E., Mulsant, B. et al. (2000). Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 23(5), 587–590.
Poolsup, N., Li Wan Po, A. and Knight, T. (2000). Pharmacogenetics and psychopharmacotherapy. Journal of Clinical Pharmacy and Therapeutics, 25(3), 197–220.
Priebe, S. (1987). Early subjective reactions predicting the outcome of hospital treatment in depressive patients. Acta Psychiatrica Scandinavica, 76(2), 134–138.
Schwartz, R. S. (2001). Racial profiling in medical research. The New England Journal of Medicine, 344(18), 1392–1393.
Teh, L. K. and Bertilsson, L. (2012). Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metabolism and Pharmacokinetics, 27(1), 55–67.
Udomratn, P. and Ng, C. (2008). Outpatients prescribing practices in Asian countries. In Ethno-Psychopharmacology: Advances in Current Practice, ed. Ng, C. H., Lin, K. M., Singh, B. and Chiu, E.. New York: Cambridge University Press, pp. 135–143.
Van Booven, D., Marsh, S., McLeod, H. et al. (2010). Cytochrome P450 2C9-CYP2C9. Pharmacogenetics and Genomics, 20(4), 277–281.
Westermeyer, J. (1989). Somatotherapies. In Psychiatric Care of Migrants: A Clinical Guide, ed. Gold, J. H.. Washington DC: American Psychiatric Press, pp. 139–168.
Yee, G. C., Stanley, D. L., Pessa, L. et al. (1995). Effect of grapefruit juice on blood cyclosporin concentration. The Lancet, 345(8955), 955–956.
Yu, S. H., Liu, S. K. et al. (2007). Psychopharmacology across cultures. In Textbook of Cultural Psychiatry, ed. Bhugra, D. and Bhui, K.. Cambridge: Cambridge University Press.
Zanger, U. M., Turpeinen, M., Klein, K. and Schwab, M. (2008). Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and Bioanalytical Chemistry, 392(6), 1093–1108.